A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women
- 1 November 2007
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Menopause
- Vol. 14 (6), 985-994
- https://doi.org/10.1097/gme.0b013e31803867a
Abstract
To compare the changes induced by oral versus transdermal estrogen therapy on the total and free serum concentrations of testosterone (T), thyroxine (T4), and cortisol (C) and the concentrations of their serum binding globulins sex hormone-binding globulin, thyroxine-binding globulin, and cortisol-binding globulin in naturally menopausal women. Randomized, open-label, crossover. Interventions included a 6-week withdrawal from previous hormone therapy (baseline), followed in randomized order by 12 weeks of oral conjugated equine estrogens (CEE) (0.625 mg/d) and 12 weeks of transdermal estradiol (TD E2) (0.05 mg/d), with oral micronized progesterone (100 mg/d) given continuously during both transdermal estrogen therapy regimens. Twenty-seven women were enrolled in the study, and 25 completed both treatment periods. The mean(SD) percentage changes from baseline of sex hormone-binding globulin, total T, and free T with oral CEE were +132.1% (74.5%), +16.4% (43.8%), and -32.7% (25.9%), respectively, versus +12.0% (25.1%), +1.2% (43.7%), and +1.0% (45.0%) with TD E2. The mean (SD) percentage changes of thyroxine-binding globulin, total T4, and free T4 with oral CEE were +39.9% (20.1%), +28.4% (29.2%), and -10.4% (22.3%), respectively, versus +0.4% (11.1%), -0.7% (16.5%), and +0.2% (26.6%) with TD E2. The mean (SD) percentage changes of cortisol-binding globulin, total C, and free C with oral CEE were +18.0% (19.5%), +29.2% (46.3%), and +50.4% (126.5%), respectively, versus -2.2% (11.3%), -6.7% (30.8%), and +1.8% (77.1%) with TD E2. Concentrations of all hormones and binding globulins were significantly different (P < or = 0.003) during administration of oral versus transdermal estrogen therapy, except for free T4 and free C. Compared with oral CEE, TD E2 exerts minimal effects on the total and free concentrations of T, T4, and C and their binding proteins.Keywords
This publication has 41 references indexed in Scilit:
- Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal womenMenopause, 2006
- Effects of aromatase inhibition on sexual function and well-being in postmenopausal women treated with testosterone: a randomized, placebo-controlled trialMenopause, 2006
- Is testosterone or estradiol the hormone of desire? A novel study of the effects of testosterone treatment and aromatase inhibition in postmenopausal womenMenopause, 2006
- Comparison of Alora® estradiol matrix transdermal delivery system with oral conjugated equine estrogen therapy in relieving menopausal symptomsClimacteric, 1999
- Exogenous Estrogen and Endogenous Sex HormonesMedicine, 1992
- Role of serum carrier proteins in the peripheral metabolism and tissue distribution of thyroid hormones in familial dysalbuminemic hyperthyroxinemia and congenital elevation of thyroxine-binding globulin.JCI Insight, 1987
- Biologic Effects of Transdermal EstradiolNew England Journal of Medicine, 1986
- An analysis of variance test for normality (complete samples)Biometrika, 1965